Want to join the conversation?
Evercore ISI analyst David Togut asks $FISV to provide an outlook for organic growth in 2017. CFO Robert Hau says that $FISV feels good about the trajectory of its growth rate. The company expects to have higher growth in 2H16 & also expects this to be the jumping point going into 2017. $FISV is on track with strategic initiatives coming on line.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.